Company Description
Until there is a cure for diabetes, Novo Nordisk will stay busy. It is one of the world's leading producers of human insulin, insulin analogues, injection devices, and diabetes education materials. Its products include modern insulin analogues Levemir and NovoLog (which mimic natural insulin regulation more closely than human insulin) and the FlexPen, a pre-filled insulin injection tool. In addition to its diabetes portfolio, the firm has products in the areas of hemostasis management (blood clotting), human growth hormone, and estrogen replacement therapy. The not-for-profit Novo Nordisk Foundation, through its
| Novo Allé | Phone: +45-4444-8888 | http://www.novonordisk.com |
| Bagsværd 2880 | Fax: +45-4449-0555 | 
Map This Company |
| Denmark |
Try a Full Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Prepare for your Sales call
Try a Small Business Subscription
Starting $89 per month
Novo Nordisk A/S Rankings
| #115 in FT Global 500 (June 2011) |
Executives
| 58 executives listed for Novo Nordisk A/S's Bagsværd, Denmark location. | ||
| Chairman | Sten Scheibye | |
|---|---|---|
| Vice Chairman | Goron Ando | |
| President and CEO | Lars Rebien Sørensen | |
Financials
| Company Type | Public - OMX Copenhagen: NOVO B Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 30,483 |
D&BiLeverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Novo Nordisk A/S now.
- Reduce risk.
- Drive greater profitability.
- Increase cash flow.
